Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Equivalents (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Cash & Equivalents for 10 consecutive years, with $188.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 15.44% to $188.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.9 million through Dec 2025, up 15.44% year-over-year, with the annual reading at $188.9 million for FY2025, 15.44% up from the prior year.
  • Cash & Equivalents hit $188.9 million in Q4 2025 for Rocket Pharmaceuticals, up from $75.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $437.2 million in Q3 2023 to a low of $32.8 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $183.6 million across 5 years, with a median of $152.1 million in 2022.
  • Biggest YoY gain for Cash & Equivalents was 192.71% in 2024; the steepest drop was 90.2% in 2024.
  • Year by year, Cash & Equivalents stood at $232.7 million in 2021, then tumbled by 39.61% to $140.5 million in 2022, then crashed by 60.22% to $55.9 million in 2023, then surged by 192.71% to $163.6 million in 2024, then grew by 15.44% to $188.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for RCKT at $188.9 million in Q4 2025, $75.9 million in Q3 2025, and $32.8 million in Q2 2025.